Athena Athena

X
[{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Leo Lens Pharma Expands Its Scientific Advisory Board","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPrint\u2122 Ophthalmics Announces It Has Initiated Its SIGHT-2 Phase 2b Clinical Study for Its Lead Asset","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"},{"orgOrder":0,"company":"Mediprint Ophthalmics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.5 million","upfrontCash":"Undisclosed","newsHeadline":"MediPrint\u2122 Ophthalmics Announces Initial Series A Funding Success","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Leo Lens Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            LL-BMT1 (bimatoprost), a drug-eluting contact lens to treat glaucoma, and is preceded by the successful completion of the Company’s SIGHT-1 study that validated the MediPrint™ process and contact lenses for treating human subjects.

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: LL-BMT1

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funds raised in this Series A round are targeted primarily to support the upcoming Phase 2b clinical study along with the end of Phase 2 meeting with the FDA for its lead glaucoma asset, LL-BMT1 (bimatoprost) in patients with open angled glaucoma or ocular hypertension.

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: LL-BMT1

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $2.5 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing March 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.

            Lead Product(s): Bimatoprost

            Therapeutic Area: Ophthalmology Product Name: LL-BMT1

            Highest Development Status: Undisclosed Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY